Skip to content

Divi#39;s Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix

A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs

Read More

​ A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish